Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Immunocore Holdings plcNASDAQ: IMCR
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit grows in line with its trailing trend
Q1 FY2026 gross profit of $106.24M rose 14.2% year over year, behind the +15.4% change in trailing-twelve-month gross profit. Sequentially, it rose 42.0% from the prior quarter. Over 3 fiscal years it compounded at +28.0% a year.
Context
- Gross profit amounted to 97.9% of revenue in FY2025, up 0.1 pp from a year earlier.
- Gross profit increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +14.2% toward the trailing-twelve-month pace of +15.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
Mixed currencies · from the income statement
- Latest · FY2025
- 291.36M USD
- Year-over-year change
- +20.2%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 291.36M | +20.2% |
| FY2024 | 2024-12-31 | 242.44M | — |
| FY2023 | 2023-12-31 | 196.57M | +41.5% |
| FY2022 | 2022-12-31 | 138.94M | +413.7% |
| FY2021 | 2021-12-31 | 27.04M | — |
Gross Profit vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.4% is the 5th highest of 11, against a peer median of -34.0%.
- Gross profit amounts to 98.8% of revenue for IMCR, versus a peer median of 91.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €1.87B EUR | -18.5% | -46.9% | 70.8% | |
| LTM Mar 2026 | $381.15M USD | +15.4% | +28.0% | 98.8% | |
| LTM Sep 2026 | $176.5M USD | +125.6% | +676.9% | 96.7% | |
| LTM Jun 2026 | $110M USD | -58.0% | +28.4% | 94.0% | |
| LTM Mar 2026 | $109.85M USD | +16.2% | -9.3% | 69.9% | |
| LTM Mar 2026 | $63.98M USD | +230.5% | +113.5% | 88.1% | |
| LTM Jun 2026 | $45.46M USD | -54.8% | — | 43.3% | |
| LTM Mar 2026 | €37.3M EUR | -74.1% | -9.9% | 100.0% | |
| LTM Mar 2026 | $11.7M USD | +129.7% | +0.9% | 54.1% | |
| FY2025 | €2.79M EUR | -77.9% | -22.6% | 100.0% | |
| FY2025 | -A$56.37M AUD | -49.5% | — | 1117.6% | |
| Peer median (excluding IMCR) | — | -34.0% | -4.2% | 91.0% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 27.04M | 144.23M | 197.39M | 247.98M | 297.57M |
| Cost of Revenue | 0 | 5.29M | 820.63K | 5.54M | 6.21M |
| Gross Profit | 27.04M | 138.94M | 196.57M | 242.44M | 291.36M |
| Gross Margin | 100.0% | 96.3% | 99.6% | 97.8% | 97.9% |
| Research & Development | 74.31M | 84.31M | 129.42M | 177.44M | 204.47M |
| Selling, General & Admin | 82.15M | 0 | 114.35M | 121.17M | 120.62M |
| Operating Expenses | 156.46M | 181.71M | 243.77M | 298.77M | 325.09M |
| Depreciation & Amortization | 5.63M | 4.41M | 3.24M | 3.36M | 2.43M |
| EBITDA | (123.58M) | (38.35M) | (40.87M) | (38.5M) | 387.18K |
| EBITDA Margin | -457.0% | -26.6% | -20.7% | -15.5% | 0.1% |
| Operating Income | (129.42M) | (42.77M) | (47.2M) | (56.28M) | (33.74M) |
| Operating Margin | -478.5% | -29.7% | -23.9% | -22.7% | -11.3% |
| Interest Income | 65K | 3.76M | 14.23M | 25.62M | 16.48M |
| Interest Expense | 5.57M | 5.41M | 4.08M | 18.84M | 12.17M |
| Other Income / Expenses | (3.92M) | 8.95M | (982.07K) | 14.01M | 19.53M |
| Income Before Tax | (133.34M) | (33.82M) | (48.19M) | (42.32M) | (14.21M) |
| Pre-Tax Margin | -493.0% | -23.4% | -24.4% | -17.1% | -4.8% |
| Income Tax Expense | 111.19K | 9.65M | (4.43M) | (1.48M) | 12.21M |
| Net Income | (133.45M) | (43.46M) | (43.75M) | (40.81M) | (26.42M) |
| Net Margin | -493.4% | -30.1% | -22.2% | -16.5% | -8.9% |
| EPS (Basic) | (3.13) | (0.95) | (0.89) | (1.02) | (0.53) |
| EPS (Diluted) | (3.00) | (0.95) | (0.89) | (1.02) | (0.53) |
| Weighted Avg Shares | 42.49M | 45.71M | 48.89M | 49.99M | 50.35M |
| Weighted Avg Shares (Diluted) | 43.86M | 45.71M | 48.89M | 49.99M | 50.35M |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.